Cargando…

Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy

CASE STUDY A 48-year-old gentleman with metastatic melanoma currently receiving the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor, ipilimumab (Yervoy), and the programmed cell death protein 1 (PD-1) inhibitor, nivolumab (Opdivo), returned for evaluation prior to receiving cycle 2. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bala-Hampton, Justin E., Bazzell, Angela F., Dains, Joyce E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347088/ https://www.ncbi.nlm.nih.gov/pubmed/30719394

Ejemplares similares

Clinical Management of Bowel Dysfunction After Low Anterior Resection for Rectal Cancer
por: Bazzell, Angela, et al.
Publicado: (2016)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Botulinum Toxin for Side-Effect Management and Prevention of Surgical Complications in Patients Treated for Head and Neck Cancers and Esophageal Cancer
por: Shaw, Leah, et al.
Publicado: (2019)

Adverse Effects of Virus-Specific T-Cell Therapy: An Integrative Review
por: Simmons, Heidi Z., et al.
Publicado: (2019)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
por: Watanabe, Satoshi, et al.
Publicado: (2020)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
por: Grossman, Joseph E., et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
por: Balaji, Aanika, et al.
Publicado: (2021)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

Anti-PD-1/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
por: Hu, Xiao, et al.
Publicado: (2023)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Publicado: (2022)

Correction: Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Publicado: (2023)

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2020)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dbeotacdaajo8vobe5n0tpdn4a